genet
immun
base
recombin
dna
technolog
attract
approach
induct
robust
antivir
antitumor
immun
condon
et
al
et
al
specif
adenovir
vaccin
encod
target
antigen
transgen
subject
extens
preclin
studi
due
establish
capac
gener
immun
respons
kim
et
al
zaric
et
al
skin
ideal
vaccin
site
contain
innat
immun
network
exquisit
respons
environment
stimuli
capabl
induc
proinflammatori
microenviron
favor
gener
strong
longlast
adapt
immun
kabashima
et
al
kashem
et
al
exploit
readili
access
cutan
immun
network
vaccin
deliveri
technolog
microneedl
array
mna
develop
precis
reproduc
target
immunolog
activ
cargo
skin
microenviron
kim
et
al
sullivan
et
al
tradit
vaccin
though
often
effect
induc
antibodi
respons
frequent
fail
gener
robust
cytotoxictcel
ctl
respons
essenti
prevent
treat
mani
cancer
infecti
diseas
current
induct
antigen
specif
cellular
immun
point
emphasi
vaccin
field
evidenc
recent
effort
gener
univers
vaccin
mutabl
infecti
agent
eg
influenza
hiv
coronavirus
target
infect
cell
express
function
essenti
viral
antigen
instead
addit
tradit
viral
surfac
protein
target
antibodi
highli
mutabl
herold
et
al
success
integr
adenovector
vaccin
onto
coat
dissolv
mna
shown
induc
efficaci
durabl
antigenspecif
respons
preclin
studi
demuth
et
al
vrdoljak
et
al
bachi
et
al
despit
promis
result
clinic
translat
adenovector
vaccin
hamper
limit
efficaci
therebi
defin
unmet
need
enhanc
immun
respons
induc
adenoviru
vaccin
gener
threedimension
multicompon
skintarget
vaccin
platform
combin
adenovirusencod
antigen
adjuv
induc
stronger
cellular
immun
respons
specif
develop
dissolv
mna
simultan
codeliv
adenovector
encod
transgen
model
antigen
ovalbumin
ova
togeth
poli
c
tolllik
receptor
trigger
doublestrand
rna
molecul
cutan
microenviron
primari
goal
enhanc
antigenspecif
cellular
immun
respons
dissolv
mna
design
mechan
penetr
superfici
cutan
layer
rapidli
dissolv
upon
insert
skin
deliv
uniform
quantiti
biocargo
defin
space
within
skin
korkmaz
et
al
enabl
local
deliveri
low
amount
drug
vaccin
achiev
high
concentr
specif
skin
microenviron
innat
cellsign
pathway
eg
downstream
tlr
wellstudi
target
ration
design
vaccin
adjuv
protein
subunit
vaccin
schijn
et
al
howev
yet
comprehens
evalu
context
recombin
viral
vector
vaccin
due
signific
mechanist
differ
includ
differ
kinet
amount
antigen
express
among
tlr
famili
member
signal
impart
uniqu
respons
secret
immunostimulatori
due
distinct
downstream
pathway
tlr
signal
adaptor
protein
use
tirdomain
contain
adapterinduc
trif
adapt
protein
subsequ
activ
boehm
et
al
schijn
et
al
use
vivo
mous
model
demonstr
mna
deliveri
agonist
poli
c
antigenencod
adenovector
result
proinflammatori
chang
target
skin
microenviron
correl
robust
antigenspecif
cellular
humor
adapt
immun
respons
studi
mice
use
week
age
experi
conduct
accord
institut
anim
care
use
committe
approv
protocol
guidelin
mechanist
simultan
codeliveri
poli
c
adenovector
vaccin
impact
proinflammatori
microenviron
immun
site
figur
dissolv
mna
incorpor
c
fabric
use
spincast
method
appli
mous
skin
min
remov
imag
mna
b
applic
obtain
use
optic
stereomicroscopi
scale
bar
vivo
multicompon
vaccin
deliveri
perform
mna
evalu
fluoresc
live
anim
imag
follow
applic
mna
incorpor
poli
c
adova
right
ear
mice
mice
imag
use
ivi
system
filter
correspond
c
demonstr
simultan
codeliveri
adova
poli
c
e
mnatreat
mous
skin
excis
imag
epifluoresc
microscopi
brightfield
microscopi
show
intercutan
deliveri
multicompon
vaccin
vivo
scale
bar
f
quantifi
transgen
ova
express
skin
mous
skin
treat
c
mna
recov
hr
ova
mrna
express
skin
quantifi
qrtpcr
data
present
mean
standard
deviat
signific
determin
twoway
anova
follow
sidak
multipl
comparison
test
p
p
bc
quantif
serum
concentr
ovaspecif
antibodi
respect
data
present
mean
standard
deviat
analyz
oneway
anova
follow
tukey
posthoc
test
ns
p
p
p
dg
investig
key
immun
mediat
skin
microenviron
induc
immun
mna
indic
compon
blank
mna
appli
describ
express
e
f
g
mrna
level
quantifi
qrtpcr
indic
time
point
data
present
mean
standard
deviat
analyz
twoway
anova
follow
tukey
multipl
comparison
test
signific
differ
treatment
group
timepoint
indic
p
p
p
dissolv
mna
obeliskshap
needl
incorpor
adenovector
without
poli
c
manufactur
use
previous
describ
mna
fabric
strategi
korkmaz
et
al
mna
design
human
applic
current
use
phase
clinic
trial
treatment
cutan
cell
lymphoma
clinicaltrialsgov
fabric
method
flexibl
rapidli
modifi
microneedl
array
design
applicationdriven
optim
bediz
et
al
balmert
et
al
briefli
mna
product
mold
prepar
use
polydimethylsiloxan
pdm
sylgard
dow
corn
base
materi
cure
agent
ratio
elastom
micromold
mna
master
mold
includ
high
microneedl
array
configur
previous
demonstr
mna
deliv
cargo
antigen
present
cell
rich
skin
microenviron
mice
human
bediz
et
al
next
pdm
product
mold
use
fabric
dissolv
mna
integr
genom
count
per
mna
poli
c
per
mna
via
multistep
spincast
techniqu
sequenti
load
poli
c
perform
via
centrifug
rpm
hr
load
load
biocargo
structur
materi
mna
prepar
dissolv
carboxymethyl
cellulos
cmc
cat
sigma
aldrich
st
loui
mo
trehalos
cat
sigmaaldrich
st
loui
mo
powder
endotoxinfre
water
hyclon
cell
cultur
grade
water
ww
ww
respect
result
ww
final
solut
concentr
load
onto
pdm
product
mold
cmctreh
hydrogel
per
mna
centrifug
rpm
hr
furthermor
blank
mna
without
biocargo
prepar
materi
composit
control
experi
fabric
mna
imag
bright
field
stereo
microscop
adenoviru
poli
c
label
use
alexa
fluor
fluoresc
dye
respect
label
viral
capsid
aminereact
alexa
dye
cat
thermofish
use
accord
manufactur
instruct
minor
modif
direct
solubil
alexa
dye
viral
suspens
avoid
use
dimethylformamid
dmf
may
impart
detriment
effect
capsid
structur
label
poli
c
amin
modif
perform
previous
describ
hermanson
et
al
briefli
mgml
poli
c
denatur
min
react
ethylenediamin
presenc
sodium
bisulfit
hr
reaction
mix
dialyz
overnight
result
amin
poli
c
ethanol
precipit
air
dri
resuspend
water
final
aminereact
nh
ester
cat
thermofish
use
label
nh
poli
c
conjug
accord
manufactur
instruct
mice
purchas
jackson
laboratori
bar
harbor
maintain
specif
pathogenfre
condit
univers
pittsburgh
use
week
age
accord
institut
anim
care
use
committe
approv
protocol
guidelin
mnamedi
skintarget
codeliveri
poli
c
demonstr
mous
mna
integr
c
creat
describ
appli
ear
anesthet
mous
min
remov
mous
imag
vivo
live
anim
imag
system
ivi
perkinelm
waltham
detect
c
mna
applic
site
imag
postprocess
use
live
imag
softwar
perkinelm
antigen
ova
specif
cellmedi
immun
determin
evalu
ovaspecif
cell
lysi
group
four
femal
mice
immun
ear
applic
adovamna
adovapoli
c
mna
blank
mna
control
twelv
day
immun
mice
assay
ovaspecif
tcell
lytic
activ
use
well
establish
techniqu
morelli
et
al
briefli
splenocyt
mice
puls
ova
deriv
siinfekl
peptid
epitop
left
unpuls
h
unpuls
splenocyt
label
low
concentr
cfse
min
antigen
puls
splenocyt
wash
stain
high
concentr
cfse
equal
popul
puls
unpuls
target
cell
splenocyt
per
mous
inject
intraven
iv
immun
mice
twenti
hour
inject
spleen
recov
anim
kill
target
cell
evalu
comparison
antigen
puls
unpuls
popul
flow
cytometri
quantifi
antigen
specif
kill
high
cfse
label
siinfeklpuls
target
specif
lysi
calcul
accord
follow
formula
ratio
cfselow
cfsehigh
mous
ratio
cfselow
cfsehigh
vaccin
mous
express
maximum
lysi
antigen
ova
specif
antibodi
respons
determin
group
four
femal
mice
immun
ear
applic
adovamna
adovapoli
c
mna
blank
mna
control
thirti
day
immun
standard
curv
ovaspecif
antibodi
obtain
blood
collect
anesthet
mice
time
sacrific
cardiac
punctur
serum
isol
use
bd
microtain
serum
separ
tube
